The Future of Skin Cancer Detection, Now FDA Cleared.

DermaSensor is more than technology; it is a commitment to helping physicians detect skin cancer at the point of care with the first AI-powered medical device for all three common skin cancers.

Now cleared by the U.S. Food and Drug Administration (FDA), DermaSensor equips physicians with immediate, accurate, and objective results that improve skin cancer detection through data-driven breakthrough technologies.

off your first 3 months
year end special
0 %

Applies to $399 monthly subscription rate only (unlimited users and patients)

After the 3-month promo, you can choose your monthly subscription
$199/month (up to 5 patients)
or 
$399/month (unlimited users & scans)

The Next Chapter in Improved Skin Cancer Detection

Explore functionalities that combine cutting-edge AI technology with non-invasive cancer detection.

Rapid Assessments, Revolutionary AI Technology

Be among the leaders in physician skin cancer lesion assessments and reserve your DermaSensor device for your office today. 

Know More. Detect Now.

Set your practice apart by being one of the first primary care physicians in the U.S. to provide non-invasive, point-of-care skin cancer testing. DermaSensor empowers physicians by providing objective, actionable results to aid in skin cancer detection by assessing cellular and sub-cellular features that cannot be seen visually or dermoscopically. 

Software Updates

Algorithm Access

Remote Device Monitoring

Validated, AI-Powered

AI Skin Cancer Detection

Cloud Storage Access

On Demand Customer Support

See Below the Surface.

Assess cellular and subcellular changes to help primary care physicians better identify skin cancers before they progress.

How it Works

DermaSensor will provide clinicians with additional information about a lesion for them to consider in their referral decision. DermaSensor™ does not definitively determine whether or not cancer is present, specify what type of cancer may be present, nor make any decision for the user.

Identify lesions suggestive of skin cancer on the patient

Apply handheld DermaSensor device to the lesion and initiate first recording

Five spectral recordings are taken from the skin lesion to complete one scan

DermaSensor’s algorithm analyzes spectral data and delivers assessment in seconds

Identify lesions suggestive of skin cancer on the patient

Apply handheld DermaSensor device to the lesion and initiate first recording

Five spectral recordings are taken from the skin lesion to complete one scan

Five spectral recordings are taken from the skin lesion to complete one scan

DermaSensor’s algorithm analyzes spectral data and delivers assessment in seconds

A result of “Monitor” suggests there is not an immediate need for specialist referral

Technology

*E Rodriguez‐Diaz, et al. Optical spectroscopy as a method for skin cancer risk assessment. Photochem and Photobiol. 2019 Nov;95(6):1441-1445.

About ESS

DermaSensor™ uses Elastic Scattering Spectroscopy (ESS), a process which evaluates how photons scatter when reflected off of different cellular structures. Malignant lesions have been reported to have different cellular and sub-cellular structures than benign lesions, scattering light differently.

Discover what other practitioners are saying.

Featured In

Spot It First

Secure your spot as a leader in skin cancer detection and healthcare innovation. Elevate your practice with DermaSensor today.

Subscribe To Our Newsletter

80-0009.1 v3

Homepage

Homepage